Survodutide is a novel dual GLP?1 and GIP receptor agonist peptide, designed for metabolic research. It activates both GLP?1 receptors and GIP receptors simultaneously, producing synergistic biological effects that regulate appetite, energy expenditure and glucose homeostasis. GLP?1 pathway activation helps slow gastric emptying, reduce food intake and improve insulin sensitivity in response to elevated blood glucose. The GIP receptor activation further amplifies metabolic benefits, supporting fat metabolism and regulating adipocyte function. Preclinical research indicates this dual receptor activation profile delivers stronger effects on body weight management and glycemic control compared with single-target GLP?1 agonists. The peptide is synthesized with optimized structural modifications to extend in-vitro stability and prolong simulated biological half-life in research models. Manufactured by Fmoc solid-phase peptide synthesis, every batch is validated by HPLC for purity, MS for molecular identity, plus residual solvent and endotoxin testing to maintain consistent quality. The lyophilized powder form protects the peptide from hydrolysis and oxidation during shipping and storage. It is widely used in in-vitro cell assays, animal model studies and pre-formulation development for metabolic disorder research. Researchers often test it alongside other incretin peptides to compare potency, receptor selectivity and dose-response curves. This product is supplied solely for laboratory investigation and research development.